MAMUL.am
Hay / Հայ | Рус | Eng | Tür
USD 402.56, EUR 440.64, RUB 4.58, GBP 505.01
+5 °C, +5 °C ... +16 °C Tomorrow:+19 °C
#SARSCoV2 mRNA vaccine development enabled by prototype pathogen preparedness
18:35, 13.06.2020 | mamul.am
19036 | 0

A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.

Share with friends
10:18, 06.03.2024
2266 | 0
to top